Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy

被引：22
作者：
Huang, Zhao-Hui [1 ,2 ]
Hua, Dong [1 ]
Li, Li-Hua [1 ]
Zhu, Jing-De [2 ]
机构：
[1] Suzhou Univ, Affiliated Hosp 4, Wuxi Oncol Inst, Wuxi 214062, Jiangsu Prov, Peoples R China
[2] Fudan Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Coll Med, Shanghai 200032, Peoples R China
来源：
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2008年 / 134卷 / 10期
关键词：
gastric cancer; chemotherapy; polymorphism; P53; protein; 5-fluorouracil; apoptosis;
D O I：
10.1007/s00432-008-0380-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objective The polymorphism of p53 codon 72 (Arg72Pro) has been suggested to play an important role in many cancers and may influence the response to chemotherapy. Our aim was to investigate the association of p53 Arg72Pro polymorphism with the clinical outcome of gastric cancer patients treated with 5-FU-based adjuvant chemotherapy. Methods The p53 codon 72 genotype was determined in blood samples from 110 Chinese patients with gastric cancer treated with 5-fluorouracil (5-FU)-based adjuvant chemotherapy, using polymerase chain reaction-ligation detection reaction (PCR-LDR) method. Results Kaplan-Meier survival analysis showed that gastric cancer patients with Pro/Pro genotype had shorter relapse-free survival (chi(2) = 10.632, P = 0.005) and overall survival (chi(2) = 7.104, P = 0.029) than patients with other genotypes. Cox multivariate analysis showed that Pro/Pro genotype was associated with statistically significant reduced relapse-free survival (adjusted OR = 3.049, 95% CI: 1.363-6.819, P = 0.007) and overall survival (adjusted OR = 2.581, 95% CI: 1.052-6.330, P = 0.038). Conclusion These results suggested that p53 codon 72 polymorphism appears to be an independent prognostic factor in gastric cancer patients treated with 5-FU-based adjuvant chemotherapy.
引用
收藏
页码：1129 / 1134
页数：6
相关论文
共 35 条
[21]   p53 polymorphic variants at codon 72 exert different effects on cell cycle progression [J].
Pim, D ;
Banks, L .
INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (02) :196-199
[22]   p53 codon 72 polymorphism and risk of cervical cancer in UK [J].
Rosenthal, AN ;
Ryan, A ;
Al-Jehani, RM ;
Storey, A ;
Harwood, CA ;
Jacobs, IJ .
LANCET, 1998, 352 (9131) :871-872
[23]   TP53 and P21 polymorphisms:: Response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer [J].
Santos, AM ;
Sousa, H ;
Portela, C ;
Pereira, D ;
Pinto, D ;
Catarino, R ;
Rodrigues, C ;
Araújo, AP ;
Lopes, C ;
Medeiros, R .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 340 (01) :256-262
[24]  
Shen HB, 2004, ONCOL REP, V11, P1115
[25]   Role of a p53 polymorphism in the development of human papillomavirus-associated cancer [J].
Storey, A ;
Thomas, M ;
Kalita, A ;
Harwood, C ;
Gardiol, D ;
Mantovani, F ;
Breuer, J ;
Leigh, IM ;
Matlashewski, G ;
Banks, L .
NATURE, 1998, 393 (6682) :229-234
[26]   Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo [J].
Sullivan, A ;
Syed, N ;
Gasco, M ;
Bergamaschi, D ;
Trigiante, G ;
Attard, M ;
Hiller, L ;
Farrell, PJ ;
Smith, P ;
Lu, X ;
Crook, T .
ONCOGENE, 2004, 23 (19) :3328-3337
[27]  
Thomas M, 1999, MOL CELL BIOL, V19, P1092
[28]   Breast cancer patients with p53 pro72 homozygous genotype have a poorer survival [J].
Tommiska, J ;
Eerola, H ;
Heinonen, M ;
Salonen, L ;
Kaare, M ;
Tallila, J ;
Ristimäki, A ;
von Smitten, K ;
Aittomäki, K ;
Heikkilä, P ;
Blomqvist, C ;
Nevanlinna, H .
CLINICAL CANCER RESEARCH, 2005, 11 (14) :5098-5103
[29]   Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients [J].
Toyama, Tatsuya ;
Zhang, Zhenhuan ;
Nishio, Mariko ;
Hamaguchi, Maho ;
Kondo, Naoto ;
Iwase, Hirotaka ;
Iwata, Hiroji ;
Takahashi, Satoru ;
Yamashita, Hiroko ;
Fujii, Yoshitaka .
BREAST CANCER RESEARCH, 2007, 9 (03)
[30]   Surfing the p53 network [J].
Vogelstein, B ;
Lane, D ;
Levine, AJ .
NATURE, 2000, 408 (6810) :307-310
1234